In a new position paper, which was officially published to coincide with a meeting of the Joint Federal Committee on 19 May in Berlin, Bio Deutschland urged that the developments in the health system be carefully dealt with, both in the interests of the patients who need medication and of the entrepreneurs who develop and manufacture it.
Reports from abroad in the middle of May stated that US President Barack Obama has made US$ 1 billion available to small biotech companies in the USA. A similar decision would also be welcomed in Germany – however, the discussions in this country focus more on helping large companies.
In a statement published on 18 May on the occasion of a hearing of the Bundestag Standing Committee on Health, Bio Deutschland urged that the path to innovative medical drugs not be blocked.
The biotech world met once again in the USA from 3 – 6 May at the BIO International Convention, which was held in Chicago this year. At the request of the Federal Economics Ministry, Bio Deutschland also provided support to the central information stand at the German Pavilion, which had been redesigned for this year’s event.
BIO Deutschland and the Liberal Institute of the Friedrich Naumann Foundation for Freedom invited guests to a joint parliamentary lunch last week.
The Federal Ministry of Health is currently drafting a bill on distributing medical drugs, which have not been authorised or licensed, in compassionate use cases (Act on Medication for Compassionate Use).
The European Committee for Standardisation (Comité Européen de Normalisation - CEN) is currently conducting a workshop on the topic of biosafety professional competence (CEN/WS 53).